The BCR-ABL1 fusion gene, resulting from t(9;22)(q34;q11) translocation (Philadelphia chromosome), occurs in 3%–5% of pediatric ALL cases and has historically been associated with poor prognosis, although outcomes have improved greatly with the introduction of tyrosine kinase inhibitors (9, 10). This evidence concerns the gene ABL1 and acute lymphoblastic leukemia.